 | |
| Names | |
|---|---|
| IUPAC name 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| EC Number |
|
| MeSH | ICI+118551 |
| UNII | |
| |
| |
| Properties | |
| C17H27NO2 | |
| Molar mass | 277.402 g/mol |
| Hazards | |
| GHS labelling:[1] | |
 | |
| Warning | |
| H315,H319,H335 | |
| P261,P264,P264+P265,P271,P280,P302+P352,P304+P340,P305+P351+P338,P319,P321,P332+P317,P337+P317,P362+P364,P403+P233,P405,P501 | |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
ICI-118,551 is a selectiveβ2 adrenergic receptor (adrenoreceptor)antagonist orbeta blocker.[1][2] ICI binds to the β2 subtype with at least 100 times greateraffinity thanβ1 orβ3, the two other known subtypes of the beta adrenoceptor.[3][4] The compound was developed byImperial Chemical Industries, which was acquired byAkzoNobel in 2008.
ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known.[5] ICI-118,551 has been used in pre-clinical studies using murine models.[6][7][8] When dissolved insaline, the compound crosses theblood–brain barrier. Common systemic doses used in rodent research are 0.5 or 1 mg/kg although efficacy has been demonstrated at doses as low as 0.0001 mg/kg (100 ng/kg) inrhesus monkeys.[9] Doses up to 20 mg/kg have been used without toxicity. At room temperature in saline, the ICI 118,551 hydrochloride is soluble to at least 2.5 mg/mL.
